Artículos de revistas
Consensus on the treatment of alopecia areata - Brazilian Society of Dermatology
Fecha
2020-11-01Registro en:
Anais Brasileiros De Dermatologia. New York: Elsevier Science Inc, v. 95, p. 39-52, 2020.
0365-0596
10.1016/j.abd.2020.05.006
S0365-05962020000700039
WOS:000614721200003
S0365-05962020000700039.pdf
Autor
Universidade Estadual Paulista (Unesp)
Universidade de São Paulo (USP)
Santa Casa Misericordia Rio de Janeiro
Universidade do Estado do Rio de Janeiro (UERJ)
Universidade Federal de São Paulo (UNIFESP)
Santa Casa Misericordia Sao Paulo
Hosp Servidor Publ Municipal
Univ Fed Golas
Univ Fed Parana
Institución
Resumen
Background: Alopecia areata is a highly frequent disease with an impact on quality of life and several treatment options with little clinical confirmatory evidence. Objective: To disseminate the recommendations of Brazilian dermatologists with expertise in the treatment of alopecia areata. Methods: Eight specialists with expertise in alopecia areata from different university centers were appointed by the Brazilian Society of Dermatology to reach a consensus on its treatment. Based on the adapted DELPHI methodology, the relevant elements were considered; then, an analysis of recent literature was carried out and the consensus was written down. Consensus on the management of alopecia areata was defined with the approval of at least 70% of the panel. Results/Conclusions: Intralesional injectable corticotherapy was considered the first optionfor localized disease in adults. In extensive cases with signs of activity, systemic cortico-steroid therapy should be considered and can be used together with immunosuppressants (corticosteroid-sparing agents). The use of an immunosensitizer (diphencyprone) is an option for stable long-term cases. Evaluation of side effects is as important as the rate of hair regrowth. (C) 2020 Sociedade Brasileira de Dermatologia. Published by Elsevier Espana, S.L.U.